Background: Previously, two reports proposed a four-stream dialysis fluid delivery system consisting of an acid concentrate, a base concentrate, a sodium chloride concentrate, and product water for correcting dysnatremias and metabolic acid-base disorders separately, by hemodialysis.
Methods: This report describes a new method for the clinical use of the previously reported four-stream dialysis fluid delivery system to treat concurrently dysnatremias and metabolic acid-base disturbances by hemodialysis. Pumps attached to each concentrate are designed to control its flow rate. Formulas were derived to determine the flow rate of each of the pumps controlling the flows of the product water (W), the base concentrate (B), and the sodium chloride concentrate (S) for any prescribed combination of sodium and bicarbonate concentrations is the final dialysis fluid. In this scheme, the flow rate of the acid concentrate (A), the concentrations of its contents in the final dialysis fluid remain constant. The flow rate ratio W:S:B:A remains also constant at 45 (i.e., 45X).
Results: The formulas were entered in an EXCEL flow sheet which determines the flow rate ratio W:S:B:A for any desired combination of sodium and bicarbonate concentrations in the dialysis fluid. The upper and lower limits of the concentrations of sodium and bicarbonate in the dialysis fluid were computed. The system has not been applied clinically. Measurements of any electrolyte concentrations have not been made.
Discussion: This system makes the treatment of profound dysnatremias, metabolic acid-base disorders, and combined dysnatremias and metabolic acid-base disorders feasible. The clinical application of the system demands prior in vitro or ex vivo studies plus fastidious and expert attention to ensure safe and dependable application.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/hdi.13205 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relationship between intraperitoneal volume and intraperitoneal pressure during peritoneal dialysis-a pilot study in adult patients.
Physiol Rep
March 2025
Renal Research Institute, New York City, New York, USA.
Monitoring intraperitoneal pressure (IPP) offers valuable insights into changes of intraperitoneal volume (IPV) during peritoneal dialysis (PD). This study aims to investigate the relationship between IPV and IPP during a PD dwell. Thirteen patients were studied during a 2-h dwell using 2 L of dialysate containing 2.
View Article and Find Full Text PDFA Case Report of Herpes Simplex Virus Associated Peritoneal Dialysis Peritonitis With Novel Use of Intraperitoneal Acyclovir.
Kidney Med
April 2025
Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Viral etiologies, such as herpes simplex virus (HSV), for peritonitis can be misclassified as culture negative peritonitis because of poor accessibility of viral testing in the effluent fluid. Inaccurate diagnosis and subsequent ineffective treatment can lead to unnecessary catheter removal for presumed refractory peritonitis. Here, we report a 73-year-old woman with a history of genital HSV-2 on continuous cyclic peritoneal dialysis who presented with HSV-2 related peritonitis.
View Article and Find Full Text PDFIntraperitoneal pressure measurements in children: a retrospective study.
Nephrol Ther
March 2025
Service de pédiatrie 1, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Background: The peritoneal dialysis (PD) regimes should be individualized based on clinical tolerance and adequacy. Routine hydrostatic intraperitoneal pressure (IPP) measurements have been suggested to define optimal intraperitoneal dialysate volume (IPV), data on applicability and variability in clinical routine are few.
Methods: We retrospectively analysed 655 IPP measurements monthly performed in 21 children on stable automated PD.
Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With Type 2 Diabetes at Cardiology, Endocrinology, and Primary Care Visits.
Mayo Clin Proc
March 2025
Center for Pharmacy Practice Innovation, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA; Department of Biostatistics, Virginia Commonwealth University School of Public Health, Richmond, Virginia, USA.
Objective: To determine the prescribing rates of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) at cardiology, endocrinology, and primary care visits in a community health system.
Patients And Methods: A cross-sectional study using electronic health record data from Bon Secours Mercy Health outpatient clinics across Virginia (2019, 2020, 2021) included patients 18 years and older with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease (CKD), and one or more outpatient visits. Adults with type 1 diabetes, stage 4/5 CKD, end-stage kidney disease, dialysis treatment, pregnancy, or hospice or palliative care were excluded.
Concurrent Control of Sodium and Bicarbonate Serum Concentrations Using a Four-Stream Hemodialysis Fluid Delivery System.
Hemodial Int
March 2025
Research Service, Department of Medicine, Raymond G. Murphy Veterans Affairs Medical Center, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA.
Background: Previously, two reports proposed a four-stream dialysis fluid delivery system consisting of an acid concentrate, a base concentrate, a sodium chloride concentrate, and product water for correcting dysnatremias and metabolic acid-base disorders separately, by hemodialysis.
Methods: This report describes a new method for the clinical use of the previously reported four-stream dialysis fluid delivery system to treat concurrently dysnatremias and metabolic acid-base disturbances by hemodialysis. Pumps attached to each concentrate are designed to control its flow rate.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!